Maninil
Brand names,
Maninil
Analogs
Maninil
Brand Names Mixture
Maninil
Chemical_Formula
C23H28ClN3O5S
Maninil
RX_link
http://www.rxlist.com/cgi/generic/glybur.htm
Maninil
fda sheet
Maninil
msds (material safety sheet)
Maninil
Synthesis Reference
Weber et al., U.S. Pat. 3,454,635 (1969)
Maninil
Molecular Weight
494.004 g/mol
Maninil
Melting Point
169-170oC
Maninil
H2O Solubility
4 mg/L
Maninil
State
Solid
Maninil
LogP
4.85
Maninil
Dosage Forms
Tablet (1.25 mg, 2.5 mg, 5 mg)
Maninil
Indication
Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
Maninil
Pharmacology
Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.
Maninil
Absorption
Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.
Maninil
side effects and Toxicity
Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.
Maninil
Patient Information
Patients should be informed of the potential risks and advantages of MICRONASE and of alternative
modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a
regular exercise program, and of regular testing of urine and/or blood glucose.
The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its
development should be explained to patients and responsible family members. Primary and secondary failure also should
be explained.
Maninil
Organisms Affected
Humans and other mammals